Business
SAREUM HOLDINGS PLC : Total voting rights
SAREUM HOLDINGS PLC : Total voting rights.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n SAREUM HOLDINGS PLC : Total voting rights(AIM : SAR)10 May 2013Sareum Holdings plc(\"Sareum\" or \"the Company\")Total Voting RightsThe Company announces that, pursuant to the requirements of the Disclosure and Transparency Rules, the total number of voting rights in respect of each class of share in issue and admitted to trading on AIM at the date of this announcement is as follows:Total number of shares in issueTotal number of voting rightsOrdinary Shares of 0.025 pence each1,521,538,263 1,521,538,263The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.For further information:Sareum Holdings plcTim Mitchell01223 497 700Sanlam Securities UK (Nomad)Simon Clements020 7628 2200Hybridan LLP (Broker)Claire Noyce, Deepak Reddy020 7947 4350The Communications Portfolio Limited (Media enquiries)Ariane Comstive [email protected] 7536 2028Notes for editors: About Sareum Holdings plcSareum is a drug discovery company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and auto-immune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.Sareum's Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. The development candidate resulting from the collaboration increases the effectiveness of current cancer therapeutics in several in-vivo cancer models.SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.Sareum Holdings plc is listed on the AIM market of the London Stock Exchange and trades under the symbol SAR. For further information, please visit www.sareum.co.ukThis announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.The owner of this announcement warran...